GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its US subsidiary Greenwich Biosciences, announced that GW Pharmaceuticals will present data from the pivotal phase 3 trials of Epidiolex (cannabidiol oral solution) in Lennox-Gastaut syndrome (LGS) and Dravet syndrome, along with other supportive data, at the American Academy of Neurology (AAN) Annual Meeting on April 21-27, 2018, in Los Angeles, California.

Highlights of the data to be presented include: Long-term safety and efficacy data in patients with LGS and Dravet syndrome; Safety and efficacy outcomes by time in Phase 3 LGS Studies; Exposure-response analysis in Phase 3 LGS studies; Results from a study evaluating the abuse potential of purified cannabidiol oral solution; Analyses of the direct cost burden associated with LGS and Dravet syndrome in the US.

“We look forward to sharing additional findings from our Epidiolex clinical program with the broader neurology community at AAN and expect that the significant continued flow of data should be supportive for neurologists as they grow their understanding of our medicine,” said Justin Gover, GW’s Chief Executive Officer. “With regulatory applications for Epidiolex accepted for review in both the US and Europe, and an expected US. launch in the second half of this year, this is a very exciting time for our Company and those awaiting this new potential treatment option.”